Canada’s Drug Agency is seeking up to 1 expert member to join our pan-Canadian Oncology Drug Review Expert Review Committee (pERC). The nomination period closes March 30, 2026.

We are particularly interested in receiving nominations from medical oncologists, hematologists, and other clinicians with expertise in the treatment and management of pediatric cancer, lung cancer, breast cancer, and head and neck cancer.

Expert members on pERC bring the following qualifications to the committee:

• a professional degree in medicine from a recognized institution
  
• in active practice and/or conducting research in either the community, hospital, and/or academic setting
  
• an understanding of the use and delivery of oncology drugs within the context of health systems in Canada.
  

pERC is composed of individuals with expertise in cancer drug therapy, drug evaluation, and drug utilization, as well as patient representatives. The committee issues drug reimbursement recommendations for oncology drugs to the participating public drug programs (except Quebec).  The approach is evidence-based, and the advice reflects medical and scientific knowledge, current clinical practice, economic considerations, ethical considerations, and the impact on patients and the public.

Click here to view the complete role description. Visit the website of Canada’s Drug Agency for complete details and to submit a nomination using their online form.